Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919425 | 0.97 | — | — | |
| SCHEMBL330125 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1MAPTEPHX1KDM5A | |
| SCHEMBL919902 | 0.92 | — | — | |
| SCHEMBL330318 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1MAPTEPHX1KDM5A | |
| SCHEMBL3026624 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1MAPTEPHX1KDM5A | |
| SCHEMBL918745 | 0.89 | SIGMAR1 (0.52) | CYP1A2SIGMAR1MAPTEPHX1KDM5A | |
| SCHEMBL308348 | 0.85 | — | — | |
| SCHEMBL920349 | 0.83 | — | — | |
| SCHEMBL330456 | 0.82 | — | — | |
| SCHEMBL11653901 | 0.82 | SIGMAR1 (0.70) | CYP1A2SIGMAR1MAPTEPHX1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279864-B | Difunctional coumarin oxime ester compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117986253-A | Blue light red phase pigment and preparation method thereof | 先尼科化工（上海）有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-115504896-B | Acrylic formate compound for LED photopolymerization, preparation method and application thereof | 湖北固润科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024078413-A1 | ACRYLOYL FORMATE COMPOUND FOR LED PHOTOPOLYMERIZATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 湖北固润科技股份有限公司 | 2024-04-18 | — | — | WO | disclosed |
| WO-2024041569-A1 | ACYLOXYPHOSPHINE OXIME ESTER COMPOUND SUITABLE FOR DEEP CURING OF UV-VIS LED LIGHT SOURCES, METHOD FOR PREPARING SAME, AND USE THEREOF | 湖北固润科技股份有限公司 | 2024-02-29 | — | — | WO | disclosed |
| CN-117142994-A | Amphiphilic polyether alpha-ketone (hetero) arylthioester compound for LED photopolymerization and preparation and application thereof | 湖北固润科技股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117142995-A | Pyruvic acid (hetero) arylthioester compound for LED photopolymerization and preparation and application thereof | 湖北固润科技股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-112094365-B | Photocurable composition containing infrared absorbing photosensitizer, initiator and alkenyl ether and/or oxetane compound | 湖北固润科技股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115504896-A | Acryloyl formate compound for LED photopolymerization, and preparation method and application thereof | 湖北固润科技股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11142511-B2 | Coumarin oxime ester compounds, preparation and use thereof | HUBEI GURUN TECHNOLOGY CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215645-A1 | Amide derivatives | OGG1, HDAC1, BCL2A1 | CYP1A2 2887/4885SIGMAR1 750/4885MAPT 4811/4885 |
| US-11142511-B2 | Coumarin oxime ester compounds, preparation and use thereof | CBR3, POR, CYP3A4 | CYP1A2 17/4885SIGMAR1 1668/4885MAPT 1764/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | CYP1A2 1483/4885SIGMAR1 2483/4885MAPT 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.